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INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare malignancy with an incidence rate of 0.5-1 per million per year. (1)  Tumor thrombus in this setting has been described but it represents an exceedingly rare surgical entity. However in one 
retrospective ACC series was reported in 25% of cases.(1) Similar to other ACC tumors, up to 50% of tumors with thrombus 
extension are functional at diagnosis.(2) Non-functional tumors are diagnosed due to mass effect or incidentally. Depending 
on the tumor thrombus level, patients can present with varicocele,(3) lower limb edema(1) or pulmonary embolus.(1) Apart 
from extension to renal vein and vena cava, extension to right atrium, splenic vein,(4) hepatic vein(5) and invasion into 
vena cava(6) have also been reported. Herein we report a case of ACC with left renal vein thrombosis in a male patient.
CASE REPORT
A 60-year-old man presented with a 3 month history of left hemi-scrotal pain. The patient did not report any urinary or 
systemic symptoms. Physical examination was unremarkable. Scrotal ultrasonography (US) was normal. Abdominal 
US demonstrated normal kidneys and a 10.7 × 8.5 cm heterogeneous mass in the upper pole of the left kidney. Color 
Doppler US identified left adrenal vein thrombosis with extension into the left renal vein. Laboratory examinations 
including CBC (hemoglobin 15.7 g/dL), liver function tests (aspartate transaminase16 U/L, alanine aminotransferase 
26 U/L, alkaline phosphatase 133 U/L, total bilirubin 0.43 mg/dL), serum creatinine (1.1 mg/dL) and electrolytes (Na 
143 mmol/L, K 3.9 mmol/L), and 24-hour urine collection (vanillylmandelic acid 1.5 mg/day, cortisol 15 µ/day) were 
within the normal ranges. Computed tomography (CT) scan with contrast (Figure 1a, 1b) confirmed the US findings. 
It demonstrated a 10 cm heterogeneous mass with Hounsfield (HU) density of 30 on non-contrast imaging. The tumor 
had washout of < 50% with attenuation of > 30 HU, 15 minutes after contrast media injection (Figure 1c, 1d, 1e). Tumor 
thrombus was seen extending into the left renal vein on the CT scan images. Chest CT was not suggestive of metastatic 
disease. After counseling, our patient elected to undergo adrenalectomy using the flank approach. Intra-operatively 
a large adrenal mass with adhesion to the upper pole of left kidney along with adrenal vein thrombosis was observed 
(Figure 2a). The tumor thrombus extended into the renal vein and inferior vena cava junction. Adrenalectomy with 
en bloc radical nephrectomy and adrenal vein tumor thrombus excision was performed (Figure 2b). The estimated 
blood loss was 700 mL and the patient required two units of intra-operative blood transfusion. No post-operative 
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Figure 1. (a and b) Computed tomography scan with coronal view. 
Arrows demonstrate tumor thrombus extension into the left renal 
vein; (c, d and e) computed tomography with axial view demonstrat-
ing large heterogeneous adrenal lesion.
Figure 2. (a) Intra-operative image demonstrating the left renal 
vein filled with the tumor thrombus; (b) gross pathology, the tumor 
thrombus within the renal vein is isolated after en bloc removal.
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complications occurred. The histopathology confirmed 
ACC with tumor thrombosis of the left adrenal vein. 
On histopathology assessment the tumor had 7 out of 9 
criteria of Weiss scoring for ACC.(7) These included high 
Fuhrman nuclear grade (3/4), mitotic counts > 5/50 per 
high power field, less than 25% clear cells composing 
tumoral cells, diffuse architecture in more than 1/3 of 
tumor, presence of necrosis, venous invasion and invasion 
of sinusoid structure. There was no evidence of renal 
involvement, and surgical margins were negative (pT3). 
The patient received adjuvant chemotherapy (mitotane 
4g/day) post operatively and currently remains on this 
treatment. At the follow up time of 5 months, the patient 
remains free of local/systemic recurrence.
DISCUSSION
ACC is a rare malignancy and ACC with tumor thrombus 
extension is a rare presentation of this malignancy. 
Depending on the extent of the tumor thrombus, patients 
can present with a variety of sign and symptoms.(3-6) After 
initial office assessment, laboratory assessment should 
include comprehensive endocrine evaluation. Acquisition 
of CT scan of chest and abdomen (adrenal protocol with 
delayed contrast media washout phase) is universal to 
all ACC staging. With regards to the tumor thrombus, 
magnetic resonance imaging (MRI) is a better modality for 
assessing the extent of the thrombus extension.(8) Further 
imaging (bone scan, head CT) is performed according to 
degree of clinical suspicion. Complete surgical resection 
with a negative margin (R0 resection) is the only 
curative option for localized disease.(9) On retrospective 
review of 275 patients with ACC undergoing primary 
tumor resection, R0 resection was associated with 25% 
reduction of local recurrence (Hazard ratio 0.74).(2) 
Presence of the tumor thrombus adds to the complexity 
of the surgery. The level of the tumor thrombus is an 
important factor for determining the surgical approach and 
type of incision. Although laparoscopic adrenalectomy 
in the setting of ACC with tumor thrombus has been 
described,(10) an open approach remains the gold standard 
surgical modality. Depending on the extent of the tumor 
thrombus, open surgery can be performed via flank, 
subcostal, chevron or thoracoabdominal approach. 
The principle of surgery is early proximal and distal 
vascular control followed by tumor thrombectomy. 
Where the inferior vena cava wall is invaded by the 
tumor, if R0 resection is possible complete excision 
and reconstruction of the cava should be performed. For 
the tumors extending into the atrium, cardiopulmonary 
bypass and cardiothoracic surgical assistance is 
necessary. Kidney sparing surgery should be performed 
where possible but one must have a low threshold for 
en bloc nephrectomy if renal invasion is suspected. 
There are no explicit recommendations to differentiate 
benign and malignant adrenocortical tumors. A few 
systems incorporating histological criteria have been 
proposed. The most frequently cited is the Weiss criteria 
revised by Aubert.(7) Our case satisfied 7 out of the 9 
criteria, which is beyond the threshold of 3 suggestive of 
malignant tumor behavior. It is noteworthy to mention 
that the morphological criteria for diagnosis of benign and 
malignant adrenocortical tumors are different between 
adult and pediatric populations.(11) Furthermore in both 
populations, when adrenocortical tumors are composed 
exclusively or predominantly of oncocytes (oncocytic 
adrenocortical neoplasms) morphological criteria for 
predicting clinical behavior are different from those 
applied in tumors with non-oncocyte morphology and Lin-
Weiss-Bisceglia score system is more appropriate.(12) 
The decision for administration of adjuvant therapy 
is made based on the tumor stage, resection status 
and the presence of Ki-67 proliferation marker.(13) 
Adjuvant therapy with mitotane has been shown to 
prolong overall survival and disease free survival.
(14,15) Close follow-up with 3 monthly CT scan imaging 
of the chest and the abdomen for the first 2 years is of 
importance, as the risk of recurrence remains high.
 
CONCLUSION
ACC is a rare condition and tumor thrombus represents 
a relatively uncommon presentation for this condition 
and where suspected needs to be further studied 
during the pre-operative work up. Complete resection 
with negative margins represents the best chance 
of cure for the patient. Adjuvant chemotherapy can 
be considered depending on final histopathology 
assessment and has been shown to improve survival.
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